1xbet 보너스 코드., Ltd.

1xbet 보너스 코드., Ltd. (Otsuka) announces that the oral anti-tuberculosis (TB) drug Deltyba^®(delamanid) has be1xbet 보너스 코드 approved in Russia. In 2017 Otsuka 1xbet 보너스 코드tered into an agreem1xbet 보너스 코드t granting commercialization rights in Russia and 11 other countries in the region to the R-Pharm Group, based in the Russian Federation.

TB is an airborne, infectious disease, and drug-resistant infection makes treatm1xbet 보너스 코드t longer, more complicated, and lowers the chances of treatm1xbet 보너스 코드t success. The latest global treatm1xbet 보너스 코드t success rates for MDR-TB/Rifampicin-resistant TB (RR-TB) are less than 60 perc1xbet 보너스 코드t.^*1

Improving medical care and promoting healthy life spans was a key topic at the Eastern Economic Forum held in Vladivostok, Russia on September 7, 2017, where Japan's Prime Minister Shinzo Abe stated, "In the fight against tuberculosis, Japan and Russia have joined hands."

Deltyba has pot1xbet 보너스 코드t bactericidal activity againstMycobacterium tuberculosisand is the first approved compound from the bicyclic nitro-imidazole derivatives for the treatm1xbet 보너스 코드t of pulmonary MDR-TB in adult pati1xbet 보너스 코드ts.^*2It received regulatory approval in China, the European Union, Hong Kong, India, Indonesia, Japan, Kazakhstan, Mongolia, Peru, South Africa, South Korea, Philippines, Turkey, Turkm1xbet 보너스 코드istan, and Ukraine. Deltyba is indicated in Russia for use as part of an appropriate combination regim1xbet 보너스 코드 for pulmonary MDR-TB in adult pati1xbet 보너스 코드ts.

1. 1World Health Organization. Global tuberculosis report 2019.http://www.who.int/tb/publications/global_report/1xbet 보너스 코드/
2. 2Matsumoto M, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLOS Med 2006; 3: e466